which provided for the development of a clinical staging system: Stage I with none or one factor and a two-year survival rate of 100 percent; Stage II with two or three factors and two-year survival of 72.2 percent; and Stage III with four or five factors and two-year survival of 0 ...
Skip to main contentSkip to article
Dr Cortes on the Phase 4 BYOND Study in Previously Treated Patients With CML Dr Girard on Findings From the LUMINOSITY Trial in c-Met–Overexpressing NSCLC Dr Adige on Improving QOL Post–Breast Cancer Treatment Dr Battiwalla on the Potential Roles of FLT3-ITD and Menin Inhibit...
Patients with refractory large B-cell lymphoma who were treated with Axi-cel had a 3-year overall survival rate of 47%, according to an updated analysis of the phase II ZUMA-1 trial.
Table 6. P-values from pair-wise t-tests for differences between absolute value of correlations of first-crop sire EBV from the different models and second-crop survival rate in first lactation1 Empty CellLMMLCMLRMTCMTRMWFM1 LCM 0.01 LRM 0.06 0.72 TCM 0.01 0.51 0.74 TRM 0.07 0.66 0.03...
The data assumes a synchronization clock for each channel's data in the case of the CMOS and LVDS outputs and a maximum data rate of 4.0 Gbps for JESD204B data transfer using the CML outputs. The reasons for the progression to JESD204B using CML drivers become obvious when looking at ...
The relapse-free survival (RFS) rate was 77% in the cohort of patients who received Orca-T vs 62% in the cohort of patients who received PTCy (HR, 0.5; 95% CI, 0.3-0.9). Furthermore, the non-relapse mortality (NRM) rates with Orca-T and PTCy were 3% and 16%, respectively (H...
Key secondary end points included investigator-assessed PFS, ORR, CR rate, and duration of response (DOR) using Lugano 2014 criteria; OS in the CD30-positive population; as well as safety and tolerability. Of the 339 patients screened, 112 and 118 were randomly assigned to the BV t...
Despite improved patient outcome using tyrosine kinase inhibitors (TKIs), chronic myeloid leukaemia (CML) patients require life-long treatment due to leukaemic stem cell (LSC) persistence. LSCs reside in the bone marrow (BM) niche, which they modify to t
Chronic myeloid leukemia (CML) is a myeloproliferative clonal disorder resulting from a neoplastic transformation of hematopoietic stem cells [1]. CML affects slightly more males than females and mainly between the fifth and sixth decades of life [2]. In Italy, the crude incidence rate is 1.61 ...